Clinical trial NCT02191826: Study of SOM0226 in Familial Amyloid Polyneuropathy
Official title: Study of SOM0226 in Familial Amyloid Polyneuropathy (FAP) Patients and Asymptomatic Carriers to Evaluate Protein Stabilization Activity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Familial Amyloid Polyneuropathy (FAP)
Keywords: Transthyretin
TTR
Amyloidosis
SOM0226
Familiar Amyloid Polyneuropathy
Lead sponsor: SOM Innovation Biotech SA
Sponsor class: INDUSTRY
Collaborators: name: Hospital Vall d'Hebron
First posted: 2014-07-16
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Clinical proof of concept study to evaluate SOM0226 efficacy in TTR Amyloidosis.

Detailed description: This is an open label interventional Phase IIa proof of concept clinical trial designed in two phases separated by a washout period of 6 weeks (± 2 weeks) , to evaluate the TTR stabilization activity of SOM0226 in healthy volunteers (wild type), TTR-FAP patients and asymptomatic carriers.

* Phase A (24 hours): SOM0226 single dose
* Phase B (32 hours): SOM0226 multiple dose

Eligibility criteria: Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the study
* Male or Female, aged 18 years or above at the time of consent
* Two cohorts defined by TTR variant (wild type: healthy volunteers; TTR mutant: asymptomatic carriers with documented mutation in TTR or diagnosed TTR-FAP patients (stage 1 or 2) not undergoing pharmacological treatment with Vyndaqel
* Body Mass Index (BMI) \> 17.5 kg/m2
* Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 2 month thereafter
* Able (in the Investigators opinion) and willing to comply with all study requirements

Exclusion Criteria:

* Female participant who is pregnant, lactating or planning pregnancy during the course of the study
* Evidence of history of clinically significant hepatic disease
* An ALT or AST measurement \> 2 times the ULN (Upper Limit of Normal)
* Scheduled elective surgery or other procedures requiring general anaesthesia during the study
* Donation of blood during the study or within the past 4 weeks
* Treatment (during the study or within the past 4 weeks) with a prescription or investigational drug for the treatment of TTR amyloidosis
* Treatment with NSAIDs (nonsteroidal antiinflammatory drug) during the study or within the past 4 weeks. The following NSAID are allowed: acetylsalicylic acid, etodolac, ibuprofen, indomethacin, ketoprofen, nabumetone, naproxen, nimesulide, piroxicam and sulindac

Primary outcomes:
measure: TTR stabilization
timeFrame: 24 hours and 32 hours
Secondary outcomes:
measure: Pharmacodynamics assessment
timeFrame: 24 hours and 32 hours
measure: Safety
timeFrame: 24 hours
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital Vall d'Hebron
state: Catalonia
Study officials:
affiliation: Hospital Vall d'Hebron
name: Josep Gámez, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gamez J, Salvado M, Reig N, Sune P, Casasnovas C, Rojas-Garcia R, Insa R. Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Amyloid. 2019 Jun;26(2):74-84. doi: 10.1080/13506129.2019.1597702. Epub 2019 May 23.